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“For every complex problem there is an answer that is 
clear, simple, and wrong.” 
 
H.L. Mencken, 1917 
  
ABSTRACT 
     The myelodysplastic syndromes (MDS) constitute a heterogeneous group of 
malignant bone marrow disorders characterized by peripheral cytopenia and increased 
risk of leukemic progression. In higher-risk MDS, Azacitidine has been shown to 
prolong survival and modulate the epigenome, although the precise mechanisms by 
which the drug exerts its effect are unknown.  
   Paper I reports the result from a Nordic study enrolling 30 transfusion-dependent 
Epo-refractory lower-risk MDS patients. Patients were treated with 6 cycles of 
Azacitidine and terminated the study if they reached transfusion independence, while 
non-responding patients received another 3 cycles combined with Epo. Five (21%) and 
one patient responded after Azacitidine and the combined treatment, respectively, and 
only 2 patients (10%) responded for more than 6 months. Toxicity was substantial, 
mainly consisting of infections. We conclude that Azacitidine can be effective in this 
cohort of patients but that the low response rate and relatively high toxicity precludes 
its recommendation as standard treatment. Targeted sequencing revealed a high 
frequency of recurrent MDS mutations without clear relation to response. 
    In paper II we cultured CD34+ progenitors from higher-risk MDS and normal bone 
marrow (NBM) with or without Azacitidine and studied the effects on DNA 
methylation and histone acetylation. We showed that the MDS genome at the global 
level is hypermethylated compared to NBM and that Azacitidine induced profound 
demethylation. Histone acetylation was decreased by treatment, which theoretically 
would counteract the transcriptional activation resulting from reduced DNA 
methylation. To further explore these effects, we repeated the same culture experiment 
in paper IV to study the effects of Azacitidine on both DNA methylation and gene 
expression. We confirmed the marked demethylating effect of Azacitidine, and by 
using RNA seq we could show that Azacitidine significantly increases gene expression 
but without association with demethylated regions. Interestingly, the repressive histone 
mark H3K9me3 increased in three demethylated genes without increased expression, 
providing a potential explanation for the lack of association between demethylation and 
increased expression. 
    In paper III we searched for factors associated with response to Azacitidine by 
studying clinical parameters (n=134); mutations (n=90); and DNA methylation (n=42) 
in patients treated with Azacitidine. Among the clinical variables, only disease duration 
before treatment predicted for poor response and survival. The group of mutations 
involved in histone modulation (ASXL1, EZH2, MLL) was associated with prolonged 
survival, contrasting previous reports on mixed MDS cohorts. Furthermore, DNA 
methylation profiles differed significantly between responding and non-responding 
patients. Analysis of 200 differentially methylated regions showed enrichment in 
pathways involved in differentiation and development. Methylation level of the most 
significant DMR, the HOXA5/A6-locus, was associated with survival.  
   To summarize, these studies show that epigenetic modifications play a significant 
role in the pathogenesis and response to treatment in MDS and that further 
understanding of chromatin modifications will be important in order to develop 
therapeutic strategies in MDS.     
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1 THE MYELODYSPLASTIC SYNDROMES 
1.1 BACKGROUND AND EPIDEMIOLOGY 
The myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal 
hematopoietic stem cell (HSC) disorders characterized by cytopenia(s), dysplasia in 
one or more cell lineages, ineffective hematopoiesis, and increased risk of progression 
to acute myeloid leukemia (AML). MDS can arise de novo or as a consequence of 
previous chemotherapy or radiation. Although the majority of MDS are characterized 
by progressive bone marrow (BM) failure, the clinical course varies substantially in the 
different subtypes with survival ranging from a few months to decades
1
. 
The incidence of MDS has been reported to between 4-10 new cases / 100 000 
inhabitants / year.
2-7
 In the Swedish quality registry covering >90% of newly diagnosed 
patients, 1247 new cases of MDS and the mixed group of myelodysplastic and 
myeloproliferative disorders (MDS/MPN) were reported between 2009 and 2012, 
corresponding to a yearly incidence of 4 / 100 000 inhabitants.  It is a disease mainly of 
the elderly and the incidence is one of the most common hematologic malignancies in 
patients over the age of 70 years, among which the annual incidence exceeds 20 per 
100,000 persons. Median age at diagnosis is around 70-75 years, with a slight 
dominance of men, see Figure 1.
2-7
  Ninety percent of MDS cases are idiopathic (de 
novo MDS) while around 10% are secondary to previous treatment with cytostatic 
drugs, in particular alkylating agents, or radiotherapy.
7
 Other risk factors identified are 
tobacco use, occupational exposure to solvents or agricultural chemicals and having a 
relative with hematological disease although these factors show only a week 
association with the disease.
8, 9
 The risk of MDS is markedly increased in certain rare 
genetic syndromes with bone marrow failure syndromes, often as a result of telomere 
dysregulation (i.e. Fanconi anemia, Shwachman-Diamond syndrome, severe congenital 
neutropenia, Dyskeratosis congenita, Diamond-Blackfan anemia).
10
  
 
1.2 CLINICAL PRESENTATION 
The clinical presentation and the natural course of MDS varies largely among 
diagnostic subgroups and between individuals. An increasing number of patients are 
diagnosed through routine blood samples obtained by the family doctor for non-MDS 
related problems. Symptoms from MDS are often related to the cytopenias where a 
majority of the patients have anemia, most often macrocytic, and some also have 
 2 
leukopenia and / or thrombocytopenia. Around half of the patients have a severe 
anemia (<100 g / L) at diagnosis.
11
 Anemia-related symptoms (e.g. fatigue, dyspnea 
and head-ache) constitute the most common clinical presentation of MDS. Other 
symptoms include infections and bleedings as a result of leukopenia and 
thrombocytopenia.  These symptoms are also the major cause of MDS-related 
mortality.
12, 13
 A minority of the patients suffer from autoimmune manifestations such 
as arthritis, pulmonary effusions and vasculitis. 
14-16
 Around one third of the patients 
transform to a secondary acute myeloid leukemia (AML).
11
 
 
Figure 1: Incidence for different age groups. Neukirchen et al, Leuk Res 2011 
 
1.3 BONE MARROW MORPHOLOGY AND CYTOGENETICS 
The bone marrow of MDS is typically hypercellular although it can be normo- or 
hypocellular. As defined by the WHO criteria (see below), at least 10% of the 
progenitors of one cell line (erythroid, myeloid or megakaryocytic) must show 
significant dysplasia for a diagnosis of MDS. Examples of dysplasia include nuclear 
abnormalities, poor granulation of the cytoplasm of granulocytes or presence of ringed 
sideroblasts. Number of cell lines involved, presence of ringed sideroblasts and 
percentage of blasts, which might be normal (<5%) or elevated defines together with 
the cytogenetic analysis the subgroup classification.
17, 18
  
Cytogenetic abnormalities are important determinants in the pathogenesis, diagnosis, 
and prognosis of MDS and have major impact on therapeutic decision-making in 
   3 
individual patients.
19-22
 Chromosomal abnormalities are detected in approximately 50% 
of patients with de novo MDS and in up to 80% in therapy-related MDS, see 
illustration in Figure 2.
19, 21
 Aberrations are most common in the RAEB-subtypes.  
In MDS, unbalanced chromosomal abnormalities reflecting gain or loss of 
chromosomal material are more prevalent in comparison to AML, while balanced 
translocation are rare.
20
 The most frequently observed chromosomal abnormality in de 
novo MDS is the interstitial deletion of the long arm of chromosome 5, with or without 
additional karyotypic abnormalities.
20, 21
 
 
Figure 2: Common chromosomal abnormalities in MDS including International Prognostic Scoring System 
predictions. Raza et al, Nature Reviews Cancer 2012 
 
1.4 CLASSIFICATION 
The World Health Organization (WHO) classification of MDS was presented in 2001 
and updated in 2008, see Table 1. It provides at date the best diagnostic approach to 
MDS. The WHO classification has considerable prognostic relevance, and its 
implementation into clinical practice is mandatory for optimal management of MDS.
13
 
The WHO classification replaced the older French-American-British (FAB) 
classification. The basis for the classification is determination of number of dysplastic 
cell lines, presence of ringed sideroblasts, percentage of blasts, myeloproliferative 
features, number of monocytes in blood and deletion of chromosome 5. In addition to 
the MDS WHO group, there is a group defining the mixed myelodysplastic / 
 4 
myeloproliferative conditions including chronic myelomonocytic leukemia (CMML) 
and atypical chronical myeloid leukemia (aCML), see Table 2.  
 
WHO subtype Peripheral blood  Bone marrow findings 
Refractory cytopenias with 
unilineage dysplasia (RCUD) 
  Refractory anemia (RA) 
  Refractory neutropenia (RN) 
  Refractory thrombocytopenia RT) 
Unicytopenia or 
bicytopenia*  
No or rare blasts 
(<1%) ** 
  
Unilineage dysplasia: ≥10% of 
the cells in one linage 
<5% blasts 
<15% of erythroid precursors 
are ring sideroblasts 
Refractory anemia with ring 
sideroblasts (RARS) 
Anemia, no blasts ≥15% of erythroid precursors 
are ring sideroblasts. Erythroid 
dysplasia only,  <5% blasts 
Refractory cytopenia with 
multilineage dysplasia (RCMD) 
Cytopenia(s)                                 
No ore rare blasts 
(<1%) 
No Auer rods                                             
<1x10/L monocytes 
Dysplasia in ≥10% of the cells 
in ≥ 2 myeloid lineages 
<5% blasts in BM 
No Auer rods, +/- 15% ring 
sideroblasts 
Refractory anemia with excess 
blasts-1 (RAEB-1) 
  
  
Cytopenia(s),  
<5% blasts,  
no Auer rods 
<1x10/L monocytes 
Unilineage or multilineage 
dysplasia 
5-9% blasts** 
No Auer rods  
Refractory anemia with excess 
blasts-2 (RAEB-2) 
  
  
Cytopenia(s) 
<5% blasts 
Auer rods +/-*** 
<1x10/L monocytes 
Unilineage or multilineage 
dysplasia 
10-19% blasts 
Auer rods +/-  
Myelodysplastic syndrome-
unclassified (MDS-U) 
  
  
  
Cytopenia(s)                                                                  
 
≤1% blasts** 
  
  
  
Unequivocal dysplasia in <10% 
of cells in ≥1 cell lines 
accompanied by a cyto-genetic 
abnormality; considered as 
presumptive evidence for MDS, 
<5% blasts 
MDS associated with isolated del(5q) Anemia; usually                 
normal or increased 
platelet count                 
No or rare blasts 
(<1%) 
Normal to increased mega-
karyocytes with hypolobated 
nuclei; <5% blasts                                             
Isolated del(5q) abnormality                     
No Auer rods 
*Bicytopenia may occassionally be observed. Cases with pancytopenia should be classified as 
MDS-U; **If the marrow blast percentage is <5% but there are 2-4% myeloblasts in the blood, the 
diagnostic classification is RAEB 1. Cases of RCUD and RCMD with 1% myeloblasts in the blood 
should be classified as MDS-U; ***Cases with Auer rods and <5% myeloblasts in the blood and 
<10% in the bone marrow should be classified as RAEB-2 
Table 1: The WHO classification 2008 of the myelodysplastic syndromes 
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Disease  Peripheral blood Bone marrow findings  
Chronic myelomonocytic 
leukaemia (CMML)  
Peripheral blood monocytosis > 
1x10
9
/l  
No BCR/ABL-1 fusion gene  
<20% blasts  
Dysplasia in one or more 
myeloid lineage
1
 
<20% blasts. Blasts include 
myeloblasts, monoblasts and 
promonocytes.  
No rearrangement of PDGFRA 
or PDGFRB  
Atypical chronic myeloid 
leukaemia, BCR-ABL1 
negative (aCML)  
Leukocytosis, neutrophilia  
Neutrophilic dysplasia  
Neutrophil precursors ≥10% of 
leukocytes  
Blasts <20%  
No BCR-ABL1 fusion gene  
No rearrangement of PDGFRA or 
PDGFRB  
Minimal basofilia  
Monocytes < 10% of leukocytes  
Neutrophil dysplasia with or 
without dysplastic lineages  
<20% blasts  
Juvenile myelomonocytic 
leukaemia (JMML)  
Peripheral blood monocytosis 
>1x10
9
/l  
<20% blasts  
Usually WBC > 10x10
9
/l  
<20% blasts.  
Evidence of clonality  
Myelodysplastic/myeloprolifer
ative neoplasm, unclassifiable 
(MDS/MPN)  
Mixed MDS and MPN features  
No prior diagnosis of MDS or 
MPN  
No history of recent growth factor 
or cytotoxic therapy to explain 
MDS or MPN features  
No BCR-ABL1 fusion gene of 
rearrangements of PDGFRA or 
PDGFRB  
Mixed MDS and MPN features  
<20% blasts  
1
Refractory anaemia with ring 
sideroblasts associated with 
marked thrombocytosis 
(RARS-T) (provisional entity)
2 
 
Persistent thrombocytosis 
>450x10
9
/l  
Anaemia  
BCR-ABL1 negative  
Cases with t(3;3)(q21;q26), 
inv(#)(q21q26) and isolated 
del(5q) are excluded  
Morphologic features of RARS; 
≥ 15% of erythroid precursors 
are ring sideroblast  
Abnormal megakaryocytes 
similar to those observed in 
BCR-ABL1 negative MPN  
1
 If myelodysplasia minimal or absent, CML can still be diagnosed if the other requirements are met and 
there is an acquired clonal cytogenetic or molecular genetic abnormality. Bicytopenia may occasionally be 
observed. Cases with pancytopenia should be classified as MDS-U  
2
 If the marrow myeloblast percentage is <5% but there are 2-4% myeloblasts in the blood, the diagnostic 
classification is RAEB-1. If the marrow myeloblast percentage is <5% and there are 1% myeloblasts in the 
blood, the case should be classified as MDS-U.  
3
Cases with Auer rods and <5% myeloblasts in the blood and <10% in the marrow should be classified as 
RAEB 
Table 2: The WHO classification  2008 of myelodysplastic/myeloproliferative neoplasms
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1.5 PROGNOSIS, RISK ASSESSMENT AND FOLLOW-UP 
The natural history of MDS varies considerably; while some patients experience an 
indolent course, others show short overall survival and rapid transformation to AML. 
Therefore, risk stratification is critical for both prognostic assessment and formulating 
treatment goals. Several prognostic scoring systems have been developed to identify 
MDS subtypes with different outcomes and to stratify patients into lower and higher 
risk subgroups. These schemes are based on morphology, peripheral blood counts and 
cytogenetics. The most commonly used prognostic tool is the International Prognostic 
Scoring System (IPSS) from 1997.
11
 The original IPSS was recently revised (IPSS-R) 
and now includes five instead of three cytogenetic prognostic subgroups; it splits 
marrow blast percentage <5% into two groups and introduces more levels of cytopenia 
(Table 3).
21
 A third scoring system, the WHO classification based prognostic score 
system (WPSS) uses the WHO classification subgroups, karyotype and in addition 
transfusion dependency which is an independent negative prognostic factor.
13
 In 
addition to the factors included in the scoring systems above, presence of fibrosis and 
co-morbidity has been identified as independent negative factors.
23, 24
  
 
Prognostic variable 0.0 0.5 1.0 1.5 2.0 3.0 4.0 
Cytogenetics 
BM blasts, % 
Hemoglobin (g/dl) 
Platelets (x10/L) 
ANC (x10/L) 
Very good 
≤2% 
≥10 
≥100 
≥0.8 
 
 
 
50-<100 
<0.8 
Good 
>2-<5% 
8-<10 
<50 
 
 
<8 
INT 
5-10% 
Poor 
>10% 
Very 
poor 
Risk category Risk score 
Very low ≤1.5 Prognostic subgroups:  
Very good: del(11q), -Y 
Good: normal,del(5q), del(12p), del(20q), double including 
del(5q) 
Poor: Inv(3)/t(3q)/del(3q), double including -7/del(7q),  
Complex karyotype: 3 abnormalities, -7 
Very poor: complex karyotype (>3 abnormalities) 
Low >1.5-3 
Intermediate >3-4.5 
High >4.5-6 
Very high >6 
Table 3. Revised IPSS, adapted from Greenberg et al., Blood, 2012 
Real-life survival data, as documented in the Swedish quality registry between 2009 
and 2012 demonstrate a median overall survival of the lower risk groups (IPSS low or 
intermediate-1) of around 4 years, while median overall survival for the higher risk 
groups (IPSS intermediate-2 or high) is only around one year, see Figure 3. 
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Figure 3: Cumulative survival stratified for IPSS risk group. Data from the Swedish quality registry 2009-
2012. 
 
1.6 PATHOGENESIS 
1.6.1 Stem cell disease 
The MDS clone has its origin in the hematopoietic stem cell compartment as 
demonstrated by clonal genetic markers in sorted HSCs and by repopulation and 
development of the MDS phenotype in mice transplantations. 
25-29
  Studies of 
fractionated compartments of the MDS clone have demonstrated that both genetic and 
epigenetic alterations can be traced back to the stem cells.
30, 31
  Furthermore, it has been 
shown that transplantation of MDS stem cells into immunodeficient mice is sufficient 
to develop the disease.
29
 Evidence of a prevailing MDS-clone, as demonstrated by 
FISH for del5q- in the stem cell compartment has been shown after lenalidomide 
treatment despite morphological and cytogenetic remission.
27
  Similarly, the 
phenotypical MDS clone within the stem cell compartment failed to be eradicated by 
Azacitidine, despite morphological remission.
32
 The non-curative potential of these 
drugs could thus be explained by a remaining MDS clone within the stem cell 
compartment which will eventually proliferate, resulting in treatment failure.  
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1.6.2 Genetic aberrations 
Through next generation sequencing, the landscape of the MDS genome has been 
unraveled and recurrent mutations in more than 40 genes have been reported to be 
associated with the MDS disease. 
33-37
 These genes can be divided into functional 
classes including spliceosome factors e.g. SF3B1 and SRSF2; epigenetic regulators e.g. 
TET2 and ASXL1; DNA methylation regulators e.g. TET2 and DNMT3A; histone 
regulators e.g. ASXL1 and EZH2; transcription factors e.g. RUNX1 and ETV6; signaling 
factors e.g. JAK2 and CBL; and cohesion factors e.g. STAG2 and RAD21. Some of the 
mutations are present in all subgroups of MDS e.g. ASXL1 while some are enriched in 
specific subgroups e.g. SF3B1 in RARS.
35
.Some of the mutations appear mutually 
exclusive to each other e.g. all spliceosome mutations while others show mutual 
association e.g. IDH2 and SRSF2.
35
  Around 70-90% of the patients have been reported 
to carry one or several mutations and the number of mutations correlates with 
survival.
35, 36
 Several of the mutations are associated with shorter survival e.g. ASXL1, 
EZH2, RUNX1 and TP53.
34-36, 38
 Our research group has demonstrated that mutations of 
TP53 in patients with del(5q) patients are common, and are associated with 
significantly shorter survival.
39
 Only SF3B1 mutation have been reported to be a 
positive prognostic marker.
40
 The impact of mutations on response to Azacitidine is 
reviewed in detail in chapter 2.10.3. One study reporting the effect of mutations after 
transplantation demonstrated a negative impact on survival of TET2, DNMT3A and 
TP53.
41
 
The high sensitivity of next generation sequencing has enabled a more detailed 
characterization of the MDS clone architecture, revealing a dynamic evolution of 
different subclones over time where Darwinian mechanisms subsequently lead to 
dominance of the subclones with the greatest survival advantage, see illustration in 
Figure 4. 
31, 42, 43
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Figure 4: Clonal evolution during progression from MDS to AML. Walter et al, New England Journal of 
Medicine, 2012. Reproduced with permission from (scientific reference citation), Copyright Massachusetts 
Medical Society 
 
1.6.3 Epigenetics in normal and cancerous cells 
The term epigenetics refers to changes in phenotype which are inherited over cell 
division, without alterations in the DNA sequence. The epigenetic regulation are  
important for cellular differentiation.
44
 There are two main mechanisms for epigenetic 
regulation. The most studied epigenetic mechanism is DNA methylation, in which 
cytosine residues of the DNA are methylated. Methylated cytosine is often located 
within or close to CpG islands, which are rich in cytosine followed by a guanine 
residue. These are often located in gene promoters and methylation in these sites results 
in inactivated transcription. The role of methylation in non-promoter regions is less 
known. A second important epigenetic mechanism is regulation of chromatin structure 
which can be formed as heterochromatin, associated with down-regulated transcription 
or euchromatin, associated with active transcription. Chromatin structure is regulated 
by enzymes which modulate the chromatin e.g. by adding histone modifications or by 
replacing the histone proteins with histone variants. Both DNA methylation and histone 
modifications are dynamically regulated during hematopoietic differentiation.
45, 46
 
Epigenetic dysregulation is a hallmark of cancer, where general hypomethylation as 
well as promotor hypermethylation are typical features.
47
 Another important feature of 
the cancer epigenome is increased epigenetic variation, as a result of stochastic drift 
due to loss of epigenetic regulation.
48
  
 
1.6.4 Epigenetics aberrations in MDS 
Several of the genes recurrently mutated in MDS are in fact epigenetic regulators and 
mutations in these genes are likely to affect the epigenome.
35, 36
  The first group of 
mutated genes is involved in the regulation of DNA methylation. TET2, which is 
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mutated in 15-25% of MDS patients, is involved in production of hydroxymethylation, 
an intermediate chemical group during DNA demethylation.
49
 It has been demonstrated 
that mutations in TET2 lead to reduced hydroxymethylation although the functional 
consequences are not clear.
50
  IDH1/2 is involved in the metabolism of 
hydroxymethylation and mutations in these enzymes result in a hypermethylated 
phenotype.
51
 Mutations in IDH1/2 have also been shown to block histone 
demethylation.
52
 DNMT3A is involved in de novo methylation and DNMT3A-mutated 
patients cluster together in genome-wide methylation analyses although the functional 
effects are yet to be described.
53
 The DNA methylation pattern has been characterized 
in a few studies, demonstrating an aberrant methylation pattern with common 
promoter-hypermethylation in line with the general pattern in cancer epigenetics.
54-56
 
Average methylation increases over time and is thought to contribute to progression of 
the disease.
55
 Several single genes, with p15 being the most studied, have been shown 
to be hypermethylated in MDS and several of them are reported to be associated with 
worse prognosis.
57-63
 Our research group showed in a previous study that promoter 
hypermethylation is associated with higher resistance to chemotherapy. 
63
 
The second group of genes is involved in regulation of chromatin structure. EZH2 
together with the rare mutations in EED, JARID2 and SUZ12 are part of the polycomb 
repressing complex 2 (PRC2), involved in trimethylation of histone 3, lysine 27 
(H3K27me3), important for stem cell function and differentiation.
64-68
 It is known that 
the EZH2 mutations in myeloid disorders result in loss of function and increased 
transcription of polycomb-target genes, e.g. HOX-genes. ASXL1 also affects PRC2 
although the exact mechanisms are still unclear.
69, 70
 Histone modifications and 
chromatin structure are much less studied than DNA methylation, partly due to 
technically more complicated assays, hence reports on histone patterns in MDS are 
sparse. One study on the activating histone mark H3K4me3 showed an increase in 36 
genes enriched for innate immunity signaling.
71
 
Several transcription factors important for hematopoietic differentiation, including 
PU.1 and GATA1 have been shown to be epigenetically dysregulated. 
72, 73
 
Furthermore, aberrant methylation of ribosomal RNA has been demonstrated in 
MDS.
74
 
There are principally two different hypotheses why epigenetic aberrations occur. The 
first is mutations in epigenetic regulators, resulting in dysregulation due to altered 
function of these regulators. This hypothesis is supported by clustering of epigenetic 
data based on mutations in specific regulators e.g. DNMT3A.
51, 53, 54, 69, 75
 Indirect 
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impact on epigenetic regulators has in a similar way been shown, for instance JAK2 
mutation downregulates a histone methyltransferase.
76
 According to the second 
hypothesis, epigenetic aberrations are a consequence of stochastic epigenetic drift with 
increased variation, supported by the fact that epigenetic variation is increasing with 
age and is considered a hallmark of cancer.
45, 48, 77, 78
  
Intriguingly, it has been postulated that age-related epigenetic drift, results in a 
decreased ability of stem cells to respond to stress and to self-renew. In this context, 
mutations in epigenetic regulators e.g. TET2 and ASXL1, gives these cells a survival 
advantage and an escape from the negative pressure of epigenetic aberrations.
79
 
 
 
1.6.5 Immunological mechanisms 
Patients with MDS sometimes present with inflammatory manifestations such as 
arthritis or vasculitis and immunosuppressant therapy is efficient in a subset of MDS 
patients.
14-16, 80
 The composition of the immune system has thus been of great interest in 
MDS research and several immunological imbalances have been identified, in 
particular within the T-cell lineage. Up-regulation of cytotoxic T-cells have been 
demonstrated in lower-risk MDS, while regulatory T-cells are up-regulated in higher 
risk MDS.
81-87
 The role of the immune system seems thus rather contrary between 
lower and higher risk MDS, where lower risk MDS is characterized by a pro-
inflammatory environment while higher risk MDS is characterized by immune 
escape.
88
 Studies on NK cells have revealed a decreased NK-cell reactivity in MDS 
patients
89-91
. Dendritic cells show reduced number and functionality in MDS with 
unknown consequences.
92, 93
 
 
1.6.6 Disturbances in the microenvironment 
Disruption of the BM microarchitecture is a common finding in MDS encompassing 
altered localization of hematopoietic cells within the bone marrow and alterations in 
components that comprise the microenvironment including edema, fibrosis, vascular 
proliferation, lymphoid aggregates and inflammatory changes.
94
 These findings 
indicate that MDS is not only a disease of hematopoietic cells but also of the tissue. 
However, whether these BM stromal changes are an epiphenomenon or a 
pathogenetically important element of the disease itself remains unclear.  In human 
MDS, xenotransplant models using immunodeficient mice have consistently shown 
poor engraftment of myelodysplastic cells and failure to confer the clinical 
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hematopoietic phenotype of human MDS suggesting a crucial role of the 
microenvironment to support the clone. Several groups have reported that abnormalities 
in stromal cells can induce MDS (or AML) in otherwise normal bone marrow cells.
95, 96
 
On the basis of these studies, a “niche-based” model of leukemogenesis in MDS has 
been proposed.
97
 
 
1.7 TREATMENT 
 
The choice of treatment in MDS is based on clinical symptoms, risk groups, 
cytogenetic and morphological features, and age. The arsenal of therapeutic 
possibilities ranges from basic treatments such as transfusions to advanced treatments 
including intensive chemotherapy and allogeneic transplantation. 
 
1.7.1 Transfusion therapy 
A majority of the patients will develop transfusion-dependent anemia at some time and 
more than 50% have a severe anemia already at diagnosis.
11
  Anemia is associated with 
increased morbidity / mortality and with decreased quality of life which is improved by 
transfusions.
13, 98, 99
 The hemoglobin level should be adapted on an individual basis by 
the patient and the physician, taking into account co-morbidities and symptoms. 
 
1.7.2  Growth factors 
Around 50% of anemic patients respond to growth factor treatment, i.e. erythropoiesis 
stimulating agents (ESA) with or without the addition of granulocyte colony 
stimulation factors (G-CSF), and the median duration of response is 2 years.
100-104
 A 
predictive model, based on serum levels of erythropoietin (S-Epo) and the red blood 
cell (RBC) transfusion rate was developed by our group to select patients with good 
probabilities for response to treatment, where S-epo and transfusion rate were negative 
prognostic factors for response.
105
 A randomized phase III study has showen that 
responders to ESA have prolonged survival compared to non-responders and two large 
retrospective studies indicate an improved survival for patients treated with ESA 
compared to untreated patients.
101, 104, 106
 
 
1.7.3 Iron chelation therapy 
All patients with a chronic need of red blood cell transfusions will eventually develop 
iron overload. In thalassemia major patients with chronic transfusion dependency from 
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early childhood, it is well known that iron overload will cause organ damage (liver, 
heart and pancreas) and eventually organ failure and death. Iron chelation decreases 
both morbidity and mortality in these patients.
107-109
 Excess iron is seen also in organs 
of heavily transfused MDS patients. Several retrospective studies have shown a 
survival benefit for patients receiving iron chelation therapy; whether this reflects a 
chelation-effect or is confounded by a more severe disease or comorbidities is however 
unclear.
110-113
 No prospective, randomized studies have addressed this question but 
extrapolated from the experience of thalassemia patients, iron chelation is generally 
recommended for patients with lower risk disease with a chronic transfusion need and 
an expected survival counted in years.
114
 Reducing the iron overload seems to improve 
bone marrow function in some cases and patients achieving transfusion independency 
when treated with iron chelation have been reported.
115, 116
 
 
1.7.4 Immunosupression 
A small group of patients with low-risk MDS can benefit from immunosuppressive 
treatment with anti-thymoglobulin (ATG) + cyclosporine-A, and response rates of 
around 30% have been reported. Hypocellular bone marrow, age below 60 years, and 
HLA DR15 positivity have been reported as associated with response.
80, 117-119
 
 
1.7.5 Immunmodulatory drugs 
Lenalidomide represents the first targeted therapy for MDS and is approved for 
transfusion dependent patients with lower risk MDS and deletion of chromosome 5 
del(5q). The specific activity in del(5q) MDS was first observed in the MDS-001 study  
in which 12 of 43 lower risk patients had del(5q) and 83% of these responded.
120
 The 
unique activity in lower risk del(5q) MDS was confirmed in a subsequent MDS-003 
study which led to approval in the United States.
121
 By contrast, the European drug 
authorities did not approve the drug as they could not exclude an association between 
treatment and leukemic transformation. The randomized double-blind phase III MDS-
004 trial aimed to validate the finding from MDS-001 and MDS-003 studies in which 
205 patients were randomized to either 10 mg lenalidomide day 1-21 every 28 days, 5 
mg daily, or placebo. The RBC-transfusion independence rate (≥26 weeks) was 56%, 
42% and 6% for lenalidomide 10 mg, 5 mg and placebo, respectively, with 
corresponding cytogenetic response rates of 29%, 15% and 0%.
122
 Median duration of 
transfusion independency in the 004 study was approximately two years, and the three 
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year overall survival and AML transformation risk were 56% and 25%, respectively in 
the lenalidomide cohorts combined. This study resulted in the European approval.  
The use of lenalidomide in non-del(5q) lower-risk, transfusion dependent MDS was 
examined in the MDS-002 clinical trial.
123
 This study had similar inclusion criteria and 
treatment schedule as the MDS-003 trial apart from the exclusion of patients with a 
del(5q) cytogenetic abnormality. The study enrolled 214 patients; 40% had RARS, and 
the majority of patients were low or INT-1 IPSS risk. The overall response rate was 
43% with 26% of patients achieving transfusion-independency with a median duration 
of response of 41 weeks.  
The observed difference in clinical responses between patients with del(5q) and non-
del(5q) MDS led to the understanding of a karyotype-specific mechanism of action. 
The ability to induce apoptosis of progenitors harboring the del(5q) abnormality is 
thought to be linked to the haploinsufficiency of one or several genes on the long arm 
of chromosome 5. The fact that patients usually achieve TI within 4-5 weeks, before 
achieving cytogenetic remission, supports the concept of activation of residual normal 
erythropoiesis. Lenalidomide has also anti-angiogenic and anti-inflammatory 
properties.
124
 In non-del(5q) disease, lenalidomide seems to enhance response of 
eryhroid precursors to different stimuli, including erythropoietin which is supported by 
the fact that lenalidomide promotes erythroid progenitor formation and expansion in 
CD34+ cells from healthy donors in vitro.
125
 
The long-term effect of lenalidomide on del(5q) patients with regard to AML 
transfusion is yet to be determined since a prospective randomized study with this 
endpoint has not been conducted. 
 
1.7.6  Chemotherapy 
Before treatment with hypomethylating agents were available, intensive chemotherapy 
was the only disease-modulating option for patients not eligible for allogeneic stem cell 
transplantation. The rate of complete remission achieved with this treatment was 
around 50%, but the relapse rates were very high and long-term survival short.  
126-128
 
Patients with a more proliferative disease, as reflected in higher cellularity, higher S-
LDH and WBC have worse response to intensive chemotherapy.
129
 After the advent of 
hypomethylating drugs, intensive chemotherapy is more rarely used but can be 
considered after failure to hypomethylating drugs in particular as a disease-controlling 
treatment prior to allogeneic stem cell transplantation.   
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1.7.7 Allogeneic stem cell transplantation 
Since allogeneic stem cell transplantation (SCT) is the only potentially curative 
treatment in MDS and all patients should be evaluated for this option. However, due to 
the potentially severe complications, transplantation can only be performed in patients 
up to around 70 years. In younger patients (<50-60 years), a myeloablative 
conditioning is normally chosen, while older patients receive a reduced intensity 
conditioning which reduces transplantation-related mortality but increases the risk of 
relapse. Long-term survival rates of
 
between 25% and 45% have been reported after 
transplantation.
130-135
  Transplantation-related mortality (TRM) after myeloablative 
conditioning and reduced intensity conditioning  has been reported to be 32% and 22%  
and relapse rate 22% vs. 45%, respectively.
130
  Due to the high risk of TRM, timing of 
transplantation is of great importance where higher-risk patients is recommended to 
proceed to SCT upfront while lower-risk patients should follow a strict surveillance 
program and be transplanted in case of signs of progression.
136
 All three prognostic 
scoring systems (IPSS, IPSS-R and WPSS) have been validated to also predict survival 
after allogeneic stem cell transplantation.
134, 137
 We have previously demonstrated that 
surveillance by using a chimerism analysis which determines the proportions of 
hematopoietic donor / recipient cells can be used to predict an impending relapse after 
SCT. However, this analysis has low sensitivity / specificity and will most likely in the 
future, be replaced by molecular markers based on gene mutations.  
 
1.7.8 Hypomethylating therapy 
There are two hypomethylating drugs available: Azacitidine, which is reviewed in 
detail in Chapter 2, and Decitabine (DAC). Both drugs result in reduced DNA 
methylation which is thought to be the principal mechanism of action although other 
mechanisms are involved, see Chapter 2. The efficacy of DAC on patients with MDS 
have been evaluated in two randomized studies, both showing responses in around 30% 
of the patients, which was significantly better than the control arm consisting of 
supportive care, although none of the studies could observe any survival benefit for 
DAC-treated patients.
138, 139
 DAC is registered for treatment of MDS in the United 
States but not in Europe. 
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1.7.9 Other epigenetic therapies 
Histone deacetylase inhibitors (HDACi) target another epigenetic mechanism resulting 
in reduced histone acetylation and increased gene expression. One of the HDACi, 
vorinostat, is approved for treatment of cutaneous T-cell lymphoma. The efficacy of 
these drugs in MDS and AML has also been evaluated in several phase I / II studies 
showing clinical activity although limited to usually between 10-20% of the patients.
140-
143
 The toxicity profile includes both hematological toxicity and side effects on the 
central nervous system such as fatigue. 
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2 AZACITIDINE 
 
2.1 BACKGROUND AND HISTORICAL OVERVIEW 
Almost 50 years ago, 5-azacitidine (Azacitidine) and 2’-deoxy-5-azacitidine 
(Decitabine) were developed as classical cytostatic agents given at high doses but were 
soon replaced by other drugs such as 5-ara-C for treatment of acute leukemias
144, 145
  In 
the 1970s the differentiation-promoting effects of Azacitidine were discovered and 
could later be coupled to the reduction of DNA methylation.
146-149
. New clinical 
studies, using lower-dosing “non-cytostatic” schedules with the hypothesis that 
demethylation could have an anti-leukemic effect, started again in the 1990s primarily 
on patients with MDS.
150
  
 
2.2 CLINICAL RESULTS IN HIGHER-RISK MDS 
Early phase I / II studies in the 1990s indicated clinical activity in higher risk MDS.
150, 
151
 Later, two large randomized phase III studies have been conducted. In the first, 
CALGB9221, 191 patients of all subtypes of MDS were enrolled and randomized to 
receive either Azacitidine at a dose of 75 mg / m
2
 subcutaneously for 7 of 28 days or to 
receive supportive care only.
152, 153
 Crossover from the control arm to Azacitidine was 
allowed after 4 months. Responses were evaluated in both arms in accordance with the 
International Working Group criteria which groups patients into complete remission 
(CR), marrow complete remission (mCR), partial remission (PR), hematological 
improvement (HI), stable disease (SD) or progressive disease (PD).
154
 Among patients 
randomized to receive supportive care, 5% met the criteria for improvement; no 
patients on this arm achieved a CR or PR. Of the 99 patients randomized to receive 
Azacitidine, 60% (n = 60) achieved a response (p < 0.0001). Responses were scored as 
CR in 7% (n=7), PR in 16% (n=16), and HI 37% (n=37). Forty-nine patients crossed 
over to receive Azacitidine, of these 47% (n=23) responded and 10% (n=5) achieved a 
CR. Patients treated with Azacitidine had a median progression free survival (PFS) of 
21 months vs. 12 months in those patients treated with supportive care alone, and this 
was statistically significant (p = 0.007), median overall survival (OS) in an intention to 
treat analysis was 20 months in the Azacitidine-treated patients vs. 14 months for those 
randomized to supportive care (p = 0.10). Thus, no statistically significant survival 
could be demonstrated, partly due to the cross-over design of this study. A landmark 
analysis performed at 6 months could, however, demonstrate a survival benefit for 
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Azacitidine-treated patients (p=0.035). In addition, this study showed improvement in 
transfusion need, effect on white blood cell and platelet counts and an improved quality 
of life. This study resulted in approval of Azacitidine in the United States. 
   The second randomized study, AZA-001, was designed to demonstrate a difference in 
overall survival, which CALGB9221failed to do.
155
 The control arm consisted of three 
possible treatments, chosen by the physician: intensive chemotherapy, low-dose 
cytarabine or supportive care. A total of 357 patients with MDS and IPSS int-2 or high, 
AML with 20-30% blasts and multilineage dysplasia or CMML with >10% blasts were 
enrolled. The primary OS endpoint of this study was met after a median follow-up of 
21.1 months. The median OS for the Azacitidine-treated patients was 24.5 months vs. 
15 months for patients assigned to the control arm (p < 0.0001), see Figure 5. Two-year 
OS also favored Azacitidine; 51% vs. 25% for the control arm (p < 0.0001). Subgroup 
analyses comparing Azacitidine and the three different therapies in the control arm 
demonstrated a survival benefit for Azacitidine compared with low-dose cytarabine 
(p=0.0006) and with supportive care (p=0.0045). There was also a survival benefit for 
Azacitidine compared with intensive chemotherapy (9.4 months) but it was not 
significant (p=0.51) probably due to the low number of patients in this group (n=42). 
Overall, 29% of those assigned to Azacitidine achieved either CR (17%) or PR (12%) 
compared with 12% (8% CR and 4% PR) assigned to the control arm (p = 0.0001). 
Any hematological improvement (HI) was observed in 49% of those treated with 
Azacitidine vs. 29% in the control arm (p = 0.0001).  Furthermore, of the 111 patients 
with red cell transfusion dependence at the time of study enrollment, 50 (45%) became 
transfusion independent in the Azacitidine group vs. 13 (11.4%) in the control arm (p= 
0.0032). In addition, treatment with Azacitidine was associated with delayed leukemic 
transformation (18 vs 12 months, p<0.0001). This study resulted in the approval of 
Azacitidine in Europe. Post-hoc analyses of the AZA001 cohort have demonstrated a 
survival benefit not only for patients achieving a response but also for patients with 
stable disease without progression during treatment.
156
 Both randomized studies show 
that responses are normally not seen before the patient has received ≥3 cycles and best 
response is often seen several cycles after the initial response.
153, 155
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Figure 5: Survival in the AZ001 study. Feneaux et al, Lancet, 2010 
 
Alternative dosing schedules have been evaluated in a study in which patients were 
randomized to receive 75 mg /m
2
 daily for 5 days, off 2 days and then on 2 days (5-2-
2), 50 mg/m 2 daily for 5 days, off 2 days and then on for 5 further days (5-2-5), and 
lastly 75 mg/m 2 daily for 5 days alone (5-0-0). These schedules seemed to result in 
similar hematological improvement rates (44%, 45%, 56%, respectively). This study 
was, however,  not designed to produce statistically significant results, nor have these 
schedules been directly compared with the approved 7 day schedule.
157
 
 
 
2.3 CLINICAL RESULTS IN LOWER-RISK MDS 
In the US, the label encompasses all patients with MDS. A subgroup analysis of 
patients (n=22) with RA/RARS in the pivotal, prospective study CALGB9221 showed 
complete remission (CR), partial remission (PR) and hematological improvement (HI) 
in 9%, 18% and 32%, respectively.
152
 A subgroup analysis from a second prospective 
study reported transfusion-independence (TI) after treatment with Azacitidine in 65% 
of previously transfusion-dependent (TD) patients (n=40) with lower-risk MDS
157
. 
Furthermore, two retrospective studies evaluated the effect of Azacitidine in lower-risk 
MDS populations. Musto et al reported CR, PR, HI of 16%, 10%, 20%, respectively 
and Prebet et al reported CR, PR, HI of 12%, 5% and 25%, respectively. None of these 
four studies employed ESA-resistance as an inclusion criterion. 
158, 159
 More recently, a 
prospective study on ESA-resistant patients with lower-risk MDS showed overall 
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response rate (ORR) of 47% and achievement of TI in previously TD patients in 33% 
of the patients.
160
  
 
2.4 ALTERNATIVE ADMINISTRATION ROUTES 
A few studies have evaluated Azacitidine given intravenously. The first compared 
pharmamacokinetic data between subcutaneous and intravenous administration.
161
 
Except peak concentration which was higher in intravenously treated patients, the 
pharmacokinetic data was almost identical. Both clinical trials using intravenous 
administration show similar response rates as previous studies on subcutaneous 
administration although they were not designed to detect survival benefit. 
161, 162
. Use of 
oral Azacitidine has been limited by drug instability but development of a film-coated 
formulation has made oral administration possible and the initial phase-I studies are 
promising.
163-165
 Larger studies on oral Azacitidine are ongoing. 
 
2.5 COMBINATION OF AZACITIDINE AND OTHER DRUGS 
The combination with HDACi has gained a lot of interest since it has been shown to 
have synergistic effects on gene expression.
166
 A few smaller studies have evaluated the 
effect of Azacitidine in combination with different HDACis and show that the 
combination is feasible and effective, however, the response rates did not seem to differ 
remarkably from studies on Azacitidine as monotherapy.
167-169
 The role of this 
combination is thus yet to be elucidated.  
Lenalidomide is registered for treatment of MDS with isolated del 5q. Several phase 
I/II studies have evaluated the effect on the combination of Azacitidine and 
lenalidomide both in cohorts with a karyotype including del5q and mixed cytogenetic 
cohorts including patients without del5q.
170-174
 The combination has shown to be 
feasible and with encouraging response rates exceeding the reported response rates on 
Azacitidine alone. 
 
2.6 AZACITIDINE AND ALLOGENEIC STEM CELL TRANSPLANTATION 
Two retrospective studies have evaluated the effect of Azacitidine as disease-
controlling treatment prior to transplantation. The first study compared outcomes after 
SCT in 54 patients with MDS or CMML who either received or did not receive pre-
transplantation Azacitidine and showed similar survival and relapse rates.
175
  The 
second trial reviewed 68 patients who either received Azacitidine or intensive 
chemotherapy as pre-transplantation treatment. The estimated OS at 1 year was 57% in 
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those treated with Azacitidine and 36% in the chemotherapy group (p=0.24). The 
results from these retrospective studies indicate that Azacitidine is not inferior to 
intensive chemotherapy prior to transplantation although no prospective randomized 
studies have tested this conclusion.
176
 
A few studies have reported the efficacy of Azacitidine used as salvage therapy after 
relapse and remission have been described for some patients.
177-181
 Most of the patients 
in these studies received concomitant donor lymphocyte infusions (DLI). Azacitidine in 
combination with DLI have also been evaluated as preemptive treatment for impending 
relapse based on increasing levels of recipient cells in the chimerism analysis and 
prevention or delay of relapse have been reported with this combination.
182
 
 
 
2.7 CLINICAL RESULTS IN ACUTE MYELOID LEUKEMIA 
The efficacy of Azacitidine in AML has been assessed in several studies. Important in 
this setting is the fact that in the previous WHO classification, patients with a previous 
MDS diagnosis and between 20-30% blasts were classified as RAEB-t, i.e. a MDS-
diagnosis, while WHO 2001 and 2008 classify these patients as AML. In the large 
randomized studies CALBG 9221 and AZA-001, patients with the former RAEB-t 
subgroup, now AML with 20-29% blasts and multilineage dysplasia, were included.
152, 
155
 Subgroup analysis of this cohort show superiority for Azacitidine-treated patients 
compared to the control arm and this subgroup is thus not different form the large 
cohort as a whole. Several studies have specifically evaluated the efficacy in AML-
patients.
183-186
 These studies show overall response rates of 32- 50%, with higher 
response rates for previously untreated patients. In summary, Azacitidine can thus be 
considered a highly active drug also in AML. Studies on the use of Azacitidine as 
consolidation therapy after remission achieved by intensive chemotherapy are ongoing. 
 
2.8 PHARMOCOKINETICS 
2.8.1 Basic pharmacokinetics 
Azacitidine is a chemically relatively unstable drug with a half-life in vitro of around 7 
hours
187-189
. Maximum concentration in vivo is reached within 30 minutes and half-life 
has been reported to be 0.3-0.7 and 0.1-0.4 hours after subcutaneous and intravenous 
injections respectively.
161, 190
 The bioavailability has been reported to be > 90%.
161, 190
  
Systemic clearance exceeds glomerular filtration rate and additional clearance through 
deamination in liver and spleen has been proposed.
191
 Concentration in patients treated 
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with standard dose (75 mg /m
2
) has been measured to 3-11µM.
161, 190
 Studies of the 
effect of factors such as age, gender, renal and hepatic impairments on pharmacokinetic 
data have not been conducted but based on the clinical studies, the safety profiles were 
not affected by these parameters.
152, 155
  Clinical drug interaction studies have not been 
performed. Pharmacokinetic studies of oral Azacitidine show a bioavailability of 6-
20%.
165
 Maximum concentration was seen after 1 hour and mean elimination half-life 
was 0.6 hours.  
 
2.8.2 Intracellular metabolism 
Transportation of nucleosides across the cellular membrane are mediated through four 
different classes of transporters but it is still not known which transporters are 
important for the transportation of Azacitidine, see Figure 6.
192
  However, one study 
shows correlation between expression of one of the transporters, ENT-1, and sensitivity 
to Azacitidine in vitro.
193
 After transportation, Azacitidine is mono, di and tri 
phosphorylated. Exactly which enzymes that are involved in this processes are 
unknown, but uridin-cytidine kinase has been proposed to be of major importance.
192
 A 
minor proportion (10-20%) of di-phosphorylated Azacitidine is being converted to 5-
aza-deoxy-cytidine-triphosphate by the ribonucleotide reductase enzyme where the 
deoxy-converted analogue can be incorporated into DNA while the non-converted 
compound can be incorporated into RNA
194
.  Interestingly, hydroxyurea has been 
shown to block the ribonucleotide reductase and thereby preventing Azacitidine from 
being incoportated to DNA.
195
  
                              
Figure 6: Intracellular metabolism of Azacitidine. Stresemann et al, Int J Cancer  2008 
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2.9 PHARMACODYNAMICS 
2.9.1 Induction of apoptosis and differentiation 
Several studies have demonstrated a direct cytotoxic effect on leukemic cells and the 
cytotoxic effect seems to be most pronounced in proliferating cells.
194, 196, 197
 Apoptotic 
activity, involving several apoptotic pathways such as activation of the TRAIL receptor 
and the bcl-2 family proteins have been shown to increase early after exposure to 
Azacitidine in vitro
197-199
. Another apoptotic pathway described more in detail is the 
DNA damage response system which can be evoked by Azacitidine mediated through 
increased expression of the transcription factor FOXO3A.  Decitabine has been shown 
to induce DNA double breaks followed by activation of the DNA damage response 
system and DNA is being repaired after drug removal.
200
 Besides pro-apoptotic 
properties, it was early demonstrated that Azacitidine had the potential to induce 
cellular differentiation of leukemic cells.
146-149
  A paradoxical effect of Azacitidine is 
observed in the clinical setting: where the kinetics of hematological toxicity observed 
during treatment, e.g. neutropenia and thrombocytopenia follows ordinary kinetics as 
compared to other cytostatic drugs with a cyclic decrease followed by recovery until 
next cycle, while the response effect arrives most often after several cycles of 
treatment, indicating a response effect other than the cytotoxicity seen in normal 
cytostatic treatment. 
 
2.9.2 Effect on stem cells 
Azacitidine can reduce clone size but repeated studies show that no complete 
eradication of MDS stem cells can be achieved.
27, 30, 32, 43
. However, long-term exposure 
in vitro has shown to inhibit self-renewal of malignant stem cells, which might 
contribute to the delay in leukemic transformation seen in Azacitidine-treated MDS-
patients.
201
 In contrast, both Decitabine and Azacitidine has been shown to rather 
increase the self-renewing capability of normal bone marrow.
202, 203
 
 
2.9.3 Effects on DNA methylation 
After Azacitidine has been metabolized to 5-aza-deoxy-cytidine-triphophate it becomes 
a substrate for the DNA replication machinery and will be incorporated into DNA as a 
substitute for cytosine. Methylation of DNA is exerted by the DNA methyl transferase 
(DNMT) family of enzymes where DNMT1 is responsible for maintaining the 
methylation pattern during replication while DNMT3A and DNMT3B exert de novo 
methylation important during the differentiation process. The DNMT enzymes 
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recognize Azacitidine-guanine nucleotides which results in an irreversible binding and 
subsequently depletion of the enzyme which in turn lead to reduced methylation.
149, 204, 
205
 The affinity for the different types of DNMT are unknown, probably all three 
enzymes are affected although the cytotoxic effect of blocking DNMT3A and DNMT3B 
has been reported to be greater than for DNMT1.
206, 207
 Besides the three DNMTs 
responsible for DNA methylation, there are two more DNMTs: DNMT2 which 
methylates tRNA and DNMT3L, which function is unknown.  
A numerous studies have shown a demethylating effect of Azacitidine, both in vitro 
and in vivo, demonstrating effect both using methods for global as well as for gene-
specific methylation level.
58, 162, 167, 197, 208-215
 Culture experiments on leukemic cell lines 
have showed increasing demethylation up to 48 h of incubation, starting already after 1 
hour of incubation.
210
 The hypomethylating effect is present at low to moderate doses 
of Azacitidine while the effect disappears with higher doses (>3uM) and demethylation 
is thus following a U-shaped curve.
211
 In vivo treatment has demonstrated a transient 
reduction of methylation, which is being restored within 4 weeks, which is the time for 
the start of the next cycle.
212
 The demethylating effect of Azacitidine seems to be non-
random and a similar demethylation pattern appears after repeated experiments.
216
 The 
demethylation effect is most prominent in regions with higher methylation levels and 
the patterns of which genes are targeted by Azacitidine are similar over several cell 
types.
215, 217
 
 
2.9.4 Effects on chromatin structure 
There is a complex cross-talk between DNA methylation and mechanisms regulating 
chromatin structure such as histone methylating and acetylating enzymes.
218
 The effect 
of Azacitidine on chromatin structure e.g. histone modifications, histone variants and 
nucleosome positioning is sparsely investigated. A few studies have demonstrated 
gene-specific change in chromatin structure for cells treated in vitro with 
Azacitidine.
219-221
 In a genome-wide study, chromatin accessibility was increased but 
only in a small minority of genes with reduced DNA methylation.
217
 Another genome-
wide study in vitro showed that the repressive marks H3K27me3 and H3K9me3 were 
reduced by Azacitidine.
222
 Insertion of the histone variant H2A.Z has been shown to be 
an essential step in for Azacitidine-induced demethylation to result in increased gene 
expression.
223
 Conversely, treatment with HDACi also results in DNA 
hypomethylation, another example of the cross-talk between the different epigenetic 
mechanisms.
224
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2.9.5 Effect on RNA and proteins 
A small fraction (10%-20%) of Azacitidine is converted by ribonucleotide reductase  to 
5-aza-deoxy-cytidine which can be incorporated into DNA and block DNA 
methylation.
194
 The reminding 80-90% is instead incorporated into RNA which has a 
destabilizing effect on the RNA resulting in reduced RNA levels and reduced total 
protein synthesis.
194, 211, 225-228
 The effect of Azacitidine on RNA has mostly studied 
tRNA and rRNA although reduced stability of mRNA also has been reported. 
Azacitidine has also been shown to be a potent inhibitor of ribonucleotide reductase 
resulting in a reduced conversion of ribonucleotides to deoxyribonucleotides necessary 
for DNA synthesis
225
. This results probably in a destabilizing effect on DNA and anti-
proliferative effect.  Since ribonucleotide reductase is necessary for the conversion of 
Azacitidine to 5-aza-deoxy-cytidine, the blockage of ribonucleotide reductase by 
Azacitidine limits its own conversion resulting in a rapid decrease in the percentage 
Azacitidine being converted to DAC and thus a reduced inhibition of DNMTs over 
time.  DNMT2 is methylating tRNA, however, it is not known if Azacitidine blocks 
DNMT2. Potentially, treatment with Azacitidine would result in reduced methylation 
and increased instability of tRNA.
229, 230
  
 
2.9.6 Effects on gene expression 
The ruling paradigm, explaining the mechanism of action of Azacitidine, has been as 
follows: demethylation of previously silenced tumor suppressor genes due to 
hypermethylated promotors result in re-expression of these genes. The evidence, at 
least in vivo is however sparse. There are studies supporting this hypothesis, which 
showed that genes with reduced methylation after treatment were accompanied by 
increased gene expression.
198, 201, 213, 222, 231
  However, in the genome-wide studies only 
a small minority of the demethylated genes also show increased expression. First, in a 
study where cells from the celline HEK 293 were incubated with Azacitidine, only a 
small minority of the up-regulated genes could be explained by changes in methylation. 
222
 A second study, using a hypermethylated colon cancer cell line, showed that only 
1.6% of the genes with Azacitidine-induced reduction of methylation also had gained 
chromatin accessibility. 
217
 However, of these genes, >90% were hypermethylated 
before start of treatment indicating that demethylation is a plausible mechanism for 
gained chromatin accessibility. Interestingly, treatment of the same cells with a 
HDACi, identified a non-overlapping set of genes, providing a rationale for the 
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combined treatment. In a third study where cells from the cell line HL60 were 
incubated with Decitabine, 160 genes were transcriptionally upregulated, 
corresponding to 3% of the total 4876 genes that were demethylated.
198
 Interestingly, 
these 160 genes were enriched for polycomb target genes involved in differentiation 
and stem cell function.  A fourth study on an AML-cell line show minor effect on gene 
expression despite clear demethylation.
215
 A few additional studies confirm a decrease 
in methylation but modest effects on gene expression and lack of association between 
demethylation and gene expression.
201, 215, 232, 233
 None of these studies have used 
primary MDS cells and none have used modern RNA sequencing for gene expression 
analysis.  
Another study demonstrated that gene expression only occurs when demethylation is 
accompanied by an open chromatin structure.
234
 Yet another possible mechanisms by 
which Azacitidine exerts its effect on gene expression could be the conformation 
change of DNMT1 induced by the binding of Azacitidine which possibly alters the 
interactions with transcription factors and chromatin regulators.
207
 
 
2.9.7 Immunological effects 
Several studies have demonstrated immunomodulatory properties of Azacitidine. 
Results from in vitro studies on regulatory T-cells (Tregs) are conflicting with reports 
of both increasing and decreasing number of Tregs as a result of Azacitidine 
treatment.
235-237
 Several reports of in vivo effects show, however, a reduction of Tregs 
even though an initial increase was observed
235, 237-239
 Interestingly, patients having a 
higher number of Tregs before start of treatment are less likely to respond. 
235
  
Furthermore, Azacitidine can induce an expansion of cytototoxic T-cells partly as a 
result of immune sensitization due to activation of cancer testis antigens.
235, 238, 240, 241
  
Studies on dendritic cells have shown that the cytokine production profile from these 
cells change during treatment although the functional consequences are unknown.
241
 In 
vitro treatment of NK cells with Azacitidine results in an increase in inhibitory ligands 
and a reduced cytolytic activity.
242-244
 The effects on NK cells in vivo remain to be 
explained.   
 
2.10 RESPONSE FACTORS  
2.10.1 Introduction 
Response to treatment is evaluated according to the International working group criteria 
which scores patients into complete remission (CR), marrow CR (mCR), partial 
   27 
remission (PR), hematological improvement (HI), stable disease (SD) and progressive 
disease (PD) , see Table 4. 
 
Category Response criteria (responses must last at least 4 weeks) 
Complete remission Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines  
  Persistent dysplasia will be noted 
  Peripheral blood: 
  Hgb ≥ 11 g/dL 
  Platelets ≥ 100 × 109/L 
  Neutrophils ≥ 1.0 × 109/L 
  Blasts 0% 
Partial remission All CR criteria if abnormal before treatment except: 
  Bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5% 
  Cellularity and morphology not relevant 
Marrow CR† Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment  
  Peripheral blood: if HI responses, they will be noted in addition to marrow 
CR 
Stable disease Failure to achieve at least PR, but no evidence of progression for > 8 weeks 
Failure Death during treatment or disease progression characterized by worsening of 
cytopenias, increase in percentage of bone marrow blasts, or progression to a 
more advanced MDS FAB subtype than pretreatment 
Relapse after CR or PR At least 1 of the following: 
  Return to pretreatment bone marrow blast percentage 
  Decrement of ≥ 50% from maximum remission/response levels in 
granulocytes or platelets 
  Reduction in Hb concentration by ≥ 1.5 g/dL or transfusion dependence 
Cytogenetic response Complete: Disappearance of the chromosomal abnormality without 
appearance of new ones 
  Partial: At least 50% reduction of the chromosomal abnormality 
Disease progression For patients with: 
  Less than 5% blasts: ≥ 50% increase in blasts to > 5% blasts 
  5%-10% blasts: ≥ 50% increase to > 10% blasts 
  10%-20% blasts: ≥ 50% increase to > 20% blasts 
  20%-30% blasts: ≥ 50% increase to > 30% blasts 
  Any of the following: 
  At least 50% decrement from maximum remission/response in granulocytes 
or platelets 
  Reduction in Hb by ≥ 2 g/dL 
  Transfusion dependence 
Table 4. International working group criteria for response. by Cheson et al, 2006 
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2.10.2 Clinical parameters 
Basic clinical data such as morphology and cytogenetics give sparse predictive 
information although blast count > 15%, extensive transfusion need, abnormal 
karyotype and previous cytarabine treatment were reported as negative predictors by 
the French MDS group.
245
  
  
2.10.3 Mutations and gene expression 
Presence of TET2-mutations and/or DNMT3A has been reported as positively 
associated with response to treatment in several studies, although not statistically 
significant in more than 2 of the studies.
59, 246-248
 High expression of BCL2L10, an anti-
apoptotic member of the Bcl-2 family, showed association with Azacitidine resistance 
in one study.
249
  
 
2.10.4 DNA Methylation profiles  
An initial reduction of methylation levels after the first treatment cycle in specific genes 
or on a global level was shown to predict a later clinical response.
58, 167, 213, 214, 231
 A 
couple of studies reported correlation between methylation level of specific genes and 
responses. First, methylation levels of p15 were lower in responders compared to non-
responders although not statistically significant.
250
 Secondly, hypermethylaton of 
BCL2L10 was linked to lower response rate which is intriguing since high expression 
of BCL2L10 also has been linked to Azacitidine-resistance.
59, 249
 In contrast, other 
studies report no correlation between baseline methylation levels and response.
58, 251
  In 
a study on global levels of DNA methylation analyzed in peripheral blood of 
mononuclear cells, no association with response was observed.
209
  
 
2.10.5 Other factors 
Higher number of Tregs resulted in lower response rates possibly as a result of 
increased immune escape.
235
 Furthermore, presence of aberrant clones in the FACS 
analysis of the MDS bone marrow was reported to be negatively associated with 
response.
252
 Moreover, lower gene expression of UCK1, one of the enzymes involved 
in the intracellular metabolism was reported to be associated with Azacitidine 
resistance and shorter overall survival.
253
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3  AIMS OF THE THESIS 
 
The purpose of this thesis was to study the clinical and molecular effects of Azacitidine 
in the myelodysplastic syndromes.  
 
Specific aims were:  
 
I. To evaluate the clinical effect of Azacitidine treatment in transfusion-
dependent, Epo-refractory patients with lower-risk MDS 
II. To investigate the cellular and epigenetic effects of Azacitidine in normal and 
higher-risk MDS progenitors in vitro 
III. To identify clinical and molecular predictors for response in patients with 
MDS treated with Azacitidine 
IV. To evaluate the differential effects on DNA methylation, gene expression and 
histone modifications in higher-risk MDS progenitors exposed to Azacitidine 
in vitro  
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4 MATERIAL AND METHODS  
 
4.1 PATIENTS 
4.1.1 Paper I 
Thirty consecutive transfusion-dependent, Epo-refractory patients with MDS and IPSS 
low or intermediate-1 risk MDS were eligible for inclusion and enrolled from 11 
centers across the Nordic region.  
 
4.1.2 Paper II and IV 
For these in vitro studies, we used bone marrow from patients with higher risk MDS 
(IPSS intermediate 2 or high), CMML-II or AML with multilinear dysplasia and 20-
29% marrow blasts and bone marrow from healthy controls. Patients were previously 
untreated with regard to chemotherapy, Azacitidine or transplantation. All patients and 
donors gave their informed consent before sampling. 
 
4.1.3 Paper III 
Clinical information was collected for all patients with MDS or AML with multilinear 
dysplasia and 20-29% marrow blasts treated with Azacitidine at the Karolinska, 
University Hospital. Biobank material based on previous bone marrow samplings for 
which the patients had given informed consent was used for targeted sequencing and 
methylation analysis. 
 
4.2 STUDY DESIGN 
4.2.1 Paper I 
This was a prospective, open-label, multicenter interventional study conducted within 
the Nordic MDS group. The study was registered at clinicaltrial.gov as NCT01048034. 
Enrolled patients received six cycles of Azacitidine, 75 mg / m
2
 for 5 consecutive days 
every 28 days, see Figure 7. Patients achieving transfusion independency terminated 
the study after six cycles. Patients who were still transfusion dependent after 6 cycles 
continued with another three cycles of Azacitidine, with the addition of Erythropoietin 
 units / week, s.c.  Efficacy assessment was performed after six cycles for all 
patients and after nine cycles for patients continuing with the combined treatment. 
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Figure 7: Study design in paper I 
 
4.3 LABORATORY EXPERIMENTS 
4.3.1 Cell sampling and sorting, paper I-IV 
Bone marrow was obtained from patients and healthy donors. Mononuclear cells 
(MNCs) were separated by density gradient technique through Lymphoprep
®
. CD34+ 
cells were separated twice by using a MACS
®
 magnetic labeling system, according to 
the manufacturers' protocols. Samples were either used directly for cell culture 
experiments or frozen as pellet in -80° C for later analysis of the DNA/RNA/Proteins. 
 
4.3.2 Suspension cultures, paper II and IV 
Cells were plated at a concentration of 1x10
6 
cells / ml in RPMI 1640-Glutamax with 
the addition of 10% fetal bovine serum. G-CSF (10 ng/ml), IL-3 (10 ng/ml) and stem 
cell factor (25 ng/ml) was added. Cells were cultured for 24h or 48h at 37°C in 5% 
CO2. Azacitidine-treated cultures used Azacitidine, diluted in sterile H2O filtered 
through 0.22 µm plastic syringe filter and added to the culture to final concentration of 
1µM. Cells were harvested and analyzed for viability, and cell count.  
 
4.3.3 Colony assays 
To explore the effect of Azacitidine on colony growth, we exposed CD34+ normal and 
MDS progenitor cells to Azacitidine (0.05-10µM) for 24 hours. Cells were then washed 
once in PBS, re-suspended in fresh medium, mixed with 4 ml of MethoCult medium 
Six cycles of 
Azacitidine 
Still transfusion 
dependent 
Another three 
cycles of Aza + 
Epo 
End of trial 
Transfusion 
independent 
End of trial 
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GFH4434 and plated in triplicates on small Petri dishes. Dishes were incubated at 37°C 
and 5% CO2 for 14 days. Erythroid colonies (CFU-E and BFU-E) and myeloid 
colonies (granulocytic colonies, CFU-G, monocytoid colonies, CFU-M and mixed 
granulocytoid / monocytoid colonies, CFU-GM) were counted and a mean value was 
calculated for each position. 
 
4.3.4 DNA extraction, paper I-IV 
Genomic DNA was extracted using Gene Elute
®
 genomic DNA extraction kit or by the 
AllPrep
® 
extraction kit. 
 
4.3.5 RNA extraction, paper IV 
RNA was extracted using the AllPrep
® 
extraction kit. 
 
4.3.6 Protein extraction, paper II 
Protein was extracted using the AllPrep
® 
extraction kit. 
 
4.3.7 Bisulphite modification, global methylation by LINE-1 and PCR, 
paper III 
Genomic DNA samples were bisulfite treated using EZ DNA Methylation Gold Kit
® 
according to standard protocol. Methylation specific assays for specific genes /LINE-1 
regions, were designed for specific genomic regions using PyroMarQ
®
 assay design 
software. Twenty ng of bisulfite treated DNA was amplified in 25µl PCR reactions 
using TaqStar
® 
polymerase) through thermal cycling of 95°C 10 Min; 40 Cycle of 
95°C; 20 sec 55°C and 30 Sec 72°C. PCR products were analyzed on a PyroMark Q24 
Pyrosequencer
®
 according to manufacturer’s instructions. 254 
 
4.3.8 Assessment of mutations, paper I, III and IV 
Patients were analyzed for 42 genes recurrently mutated in myeloid disorders using 
Haloplex
TM
 target enrichment technology, followed by high throughput sequencing. 
The Haloplex
TM
 target enrichment kit G9901A/B was designed using SureDesign
tm
 
wizard and we achieved 99.2% coverage of the 42 selected genes. All samples were 
individually barcoded during enrichment and sequenced using Illumina HiSeQ 2000 
system at the Sci-Life lab, Stockholm, Sweden. Sequencing reads were mapped over 
Human genome 19 by Bowtie and the variants were called using SAMTOOLS. 
255, 256
 
The minimum coverage to consider in the analysis was 300 reads and the allele should 
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have a minimum of 5% of reads. Sequence variations were annotated and functionally 
classified using ANNOVAR
257
. Variants previously reported as germline 
polymorphisms in the 1000 genome and the ESP5400 databases were excluded. 
258, 259
 
Variants located in non-coding regions as well as synonymous variants were filtered 
out.  
 
4.3.9 Illumina methylation array, paper II-IV 
Five hundred ng of DNA from bone marrow MNC and CD34+ cells was processed 
using Illumina-supplied reagents and conditions at a core facility of the Karolinska 
Institute. After hybridization and scanning, the raw data files were quality checked in 
GenomeStudio. Data was imported into R v. 3.1 and pre-processed using the R 
BioConductor packages lumi, methylumi and minfi packages.
260-263
 Identification of 
differentially methylated sites and regions were analyzed using the BioConductor 
packages limma, DMRCate and minifi.
264
 
261, 265
 Pathway analysis was performed using 
GO-miner.
266
 
 
4.3.10 Western blot, paper II 
Protein concentration was determined by Bradford. Samples were boiled, and equal 
amounts of protein loaded on a 4-20% TrisHCK gel, separated by SDS-PAGE and 
transferred to nitrocellulose membrane, incubated in blocking buffer for 1 hour, probed 
with respective primary antibody overnight (H3K9ac rabbit polyclonal, ab1191; 
H3K27ac rabbit polyclonal, ab4729; H3 rabbit polyclonal, ab1791; and H4 mouse 
monoclonal loading control, ab31830; all from Abcam, diluted in 1:1000). After 
washing with PBST, secondary fluorescent signal was detected using LiCor
®
 Odyssey 
infrared scanner. The Licor
®
 Odyssey software version 3.0 was used for signal intensity 
calculations. 
 
4.3.11 RNA sequencing, paper IV 
The previously published single-cell tagged reverse transcription (STRT) protocol was 
applied using 10 ng total RNA as template and following minor modifications.
267
  
Forty-eight barcodes were used, the cell capture buffer contained 0.1% Triton X-100, 
400 nM T30-VN-oligo and 2 µM TSO without magnesium chloride. All 48 cDNAs 
were pooled into one tube using 10% PEG-6000 and a final concentration of 0.9 M 
NaCl. Purified cDNA was first amplified using 14 cycles of PCR and later an 
additional 10 cycles to introduce a complete set of adapters for Illumina sequencing. 
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The ready library was size-selected using the sequential AMPure XP bead selection 
protocol
 
(https://www.neb.com/protocols/ 1/01/01/size-selection-e6270) where 0.7× 
and 0.22× ratios were used.  
Sequencing reads obtained from the STRT library were preprocessed by STRTprep
268
 
to (i) demultiplex by the sample barcodes, (ii) exclude redundant reads to reduce PCR 
bias by unique molecular identifier (UMI)
269
, (iii) align the reads to human reference 
genome hg19 and spike-in RNA sequences by TopHat
270
, (iv) quantitate the expression 
levels by 50 base pairs (bp) strand-specific windows sliding in 25 bp step, and (v) 
perform the basic quality check of the library and the sequencing. Next, we extracted 
the 50 bp windows with expression levels that showed significantly more fluctuation in 
the target samples (potentially relevant biological variation) than in the spike-in RNAs 
(technical variation), and identified and excluded outlier samples in the expression 
levels of the fluctuated regions by PCA. The fluctuated regions contain many regions 
regulated by various factors, not only by treatments but also by gender, age, and so on. 
We therefore also tested differential expression of the fluctuated regions between 
control and the treatment of the targets by SAMstrt
271
; we specified different 
permutation blocks for different patients as the paired statistics. 
 
4.3.12 Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) 
ChIP assay was performed using the iDeal® Chip-seq kit from Diagenode, using 
250 000 CD34+cells per ChIP. Briefly, after 24h incubation with or without 
Azacitidine, cells were crosslinked for 8 min by adding formaldehyde (37 %) to the 
growth media to a final concentration of 1% at room temperature. Crosslinking was 
quenched by adding 2.5 M glycine to a final concentration of 125 mM, and cells were 
washed twice with ice cold PBS. Cell nuclei were extracted by resuspending cells in 
lysis buffer 1 (iDeal® ChiP-seq Diagenode) for 10 min at 4°C and lysis buffer 2 
(iDeal® ChiP-seq Diagenode) for 10 min at 4°C. Chromatin was fragmented using the 
Bioruptor sonicator (Diagenode) for 25 min (30s pulses) to produce fragments 200-500 
nt in size. Antibodies used were H3K9Me3 (Abcam, #ab8988), and H3 (Diagenode). 
Immunoprecipitates were collected using protein A coated magnetic beads from the 
iDeal® Chip-seq kit (Diagenode). Precipitated DNA was eluted by 30 min incubation 
on rotating wheel in RT, and crosslinking was reversed by overnight incubation at 
65°C. The ChIP DNA was extracted with a PCR purification kit (MiniElute®,Qiagen). 
qPCR validation of enrichment using the primers specific for the selected genes. Each 
gene was assessed by ChIP qPCR for repressive mark H3K9me3 in three different 
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patients, technical triplicates were run 4-5 times per gene. GAPDH was used for 
positive control and Ct levels of GAPDH were unchanged upon treatment. For qPCR, 
200nM primer (TaqCopenhage) and SybGreen® (Bio-Rad) on the CFX96 Touch® 
Real-Time PCR Detection System (Bio-Rad) was used. Normalized gene expression 
was calculated using the CFX manager software (Bio-Rad), and expression was 
normalized to the percentage of input.  
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5 RESULTS AND DISCUSSION 
5.1 PAPER I 
LIMITED CLINICAL EFFICACY OF AZACITIDINE IN TRANSFUSION-DEPENDENT, 
GROWTH FACTOR RESISTANT, LOW- AND INT-1 RISK MDS. RESULTS FROM THE 
NORDIC NMDSG08A PHASE II STUDY  
 
Azacitidine has been confidently shown to prolong survival in high-risk MDS, while 
data on lower-risk MDS patients is limited to subgroup analysis and retrospective 
studies. This study aimed to evaluate the efficacy of Azacitidine treatment in a cohort 
of transfusion-dependent, epo-refractory patients with lower-risk MDS (IPSS low or 
int-1).  
We enrolled 30 patients from 11 Nordic centers in a prospective study and defined the 
proportion of patients achieving transfusion independency as primary endpoint. All 
patients were refractory to EPO/G-CSF treatment or scored “low” probability for 
response according to a prognostic score model and had a transfusion need ≥4 units 
over 8 weeks. 
99
  Included patients had a median number of transfused units of 7 (4-14) 
during the 8 weeks preceding inclusion. Median platelet and ANC count pre-treatment 
was 220x10
9
/L (22-1468) and 2.1x10
9
/L (0.3-15.1), respectively. Severe 
thrombocytopenia (<30) and neutropenia (<0.5) was observed in 3 and 3 patients, 
respectively. Ten patients pre-terminated the study; five due to sustained cytopenia 
after start of treatment; two due to death (one sudden death and one neutropenic 
septicemia); two due to patient’s wish and one due to investigators choice. Thirty-eight 
serious adverse events were reported in 18 patients with infection (n=28) being the 
most common. Nadir values after each cycle of Azacitidine were seen at week 3 for 
platelet count (median 130x10
9
/L) and at week 4 for neutrophil count (median 
1.2x10
9
/L), respectively. 
Twenty-four patients were evaluable for treatment with Azacitidine alone and 15 
patients for Azacitidine+Epo. Transfusion independency was achieved in 5 patients 
(21%) after Azacitidine treatment alone, and in one additional patient after 
Azacitidine+Epo, see Figure 8. The response duration was relatively short with only 2 
patients being transfusion independent for more than 6 months.  
Recurrent mutations were found in all but three sequenced patients, rendering this 
lower-risk cohort a mutational frequency at least as high as in previous reports on MDS 
of all risk groups, see Figure 9.
35, 36
 A majority of the patients carried a mutation in a 
splice factor gene and / or in one or several of the genes involved in epigenetic 
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regulation.  None of the mutations predicted for a response to Azacitidine.  Notably, 
mutations in two genes; DNMT3A (n=4), and SF3A1 (n=3) were only observed in non-
responders, which deserve further investigation. 
In summary, Azacitidine can induce transfusion independency in patients with 
transfusion dependent, lower-risk MDS, but the response rate is lower in this cohort of 
documented EPO-G-CSF-refractory patients compared to previous reports of less well-
controlled cohorts. Since toxicity is substantial, candidate patients for this treatment 
must be selected carefully. The combination of Azacitidine and Epo can be effective in 
rare cases.  
 
 
Figure 8   A - Outcome after Azacitidine as monotherapy and the combined treatment of Azacitidine and 
Erythropoietin (Epo). Response defined as transfusion independence. B – Duration of response. C – Overall 
survival. D – Leukemic transformation 
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Figure 9: Spectrum of mutations and cytogenetic aberrations in responders and non-responders 
  
 
5.2 PAPER II 
AZACITIDINE INDUCES PROFOUND GENOME-WIDE HYPOMETHYLATION IN PRIMARY 
MYELODYSPLASTIC BONE MARROW CULTURES BUT MAY ALSO REDUCE HISTONE 
ACETYLATION. 
 
This study evaluated the effect of Azacitidine in primary bone marrow progenitors 
from MDS patients. We studied the effect on growth, colony formation, DNA 
methylation and histone acetylation.  
In the cell suspension assays, we observed that doses up to 5 µM did not affect cell 
growth or viability. Actually, the absolute number of cells per ml was higher in 
Azacitidine treated positions than in controls in 1/10 NBM samples and 4/10 MDS 
samples. Neither was there any inhibitory effect on colony formation after exposure to 
Azacitidine in doses up to 0.5µM for 24 hours. In fact, the number of colonies 
(especially erythroid colonies) increased by > 70% with lower doses of Azacitidine in 
5/9 MDS samples and 5/13 NBM samples. This may suggest a direct stimulatory effect 
of Azacitidine on erythropoiesis. The seemingly non-toxic effect of the drug on normal 
bone marrow progenitors is a useful finding since it may support the use of the drug as 
maintenance after allogeneic stem cell transplantation without toxicity on donor 
hematopoiesis. 
Assessment of global methylation by pyrosequencing of LINE-1 repetitive elements 
showed a significant decrease in methylation after incubation with 1µM of Azacitidine 
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for 24h in samples from NBM as well as for MDS (p=0.001 and 0.02, respectively). No 
further hypomethylating effect was observed with higher doses. There were 32 155 
significantly differentially methylated sites in untreated MDS vs. untreated NBM, see 
Figure 10. The majority (89%) of the sites were more methylated in MDS than in 
NBM. Azacitidine at 1 µM for 24h induced a marked genome-wide reduction of 
methylation levels in CD34+ MDS progenitors and induced significant alterations at 
15 531 examined sites, whereof 96% were less methylated after Azacitidine treatment. 
Importantly, the demethylating effect was not promoter specific but included to an 
equal degree non-promoter CpG-sites. Interestingly, only 1% of the sites that were 
aberrantly methylated in untreated MDS vs NBM, changed by Azacitidine treatment. In 
these 239 sites, Azacitidine restored the methylation level towards that of NBM. 
Unexpectedly, only 3% (8/239) corresponded to gene promotors which suggests that 
other effects than re-expression of genes silenced by aberrant DNA hypermethylation 
are activated by Azacitidine. NBM progenitors also became demethylated but the 
difference did not reach statistical significance which indicates differential effects on 
normal and MDS progenitors. 
The effect of Azacitidine on histone modifications has been sparsely investigated. Our 
initial hypothesis was that H3K9ac and H3K27ac (markers of active chromatin) would 
increase after Azacitidine treatment due to chromatin activation within previously 
silenced promoter regions. By contrast, we showed a decrease of histone acetylation 
after Azacitidine treatment. H3K9ac decreased in eight of eight examined patients from 
which we had enough sample material (average decrease 48%, P<0.05) and H3K27ac 
decreased in five of six examined patients (average 35%, P=0.15) as assessed by 
western blot analysis. This pattern was not observed in normal CD34+ cells, which 
remained largely unaffected or showed slightly increased acetylation. H3 and H4 were 
run as loading controls and showed stable and similar loading, which ensures that the 
effects did not reflect alterations in global H3/H4 ratio. We hypothesize that the 
observed pattern may be due to interplay between DNA methylation and chromatin 
structure; if gene silencing by DNA methylation is lost, histone modifications will keep 
the chromatin repressed. Upregulation of histone deacetylase by demethylation after 
Azacitidine treatment, and hence, a global reduction of histone acetylation could be one 
reason for resistance or incomplete clinical response to Azacitidine. Interestingly, we 
found that the gene encoding for the histone deacetylase enzyme HDAC4 became 
hypomethylated in MDS progenitor cells upon Azacitidine treatment. Thus, it is 
 40 
possible that increased HDAC4 levels are contributing to the observed reduction of 
H3K27ac and H3K9ac. 
 
 
Figure 10: Genome-wide DNA-methylation (a–d) (a) Venn diagram showing number of differentially 
methylated genes between MDS vs. NBM and treated vs. untreated cells  (b) Volcano plot showing difference 
in methylation untreated MDS vs untreated NBM. Blue dots represent data above the significance level. (c) 
Volcano plot showing difference in methylation between treated MDS vs untreated MDS. Blue dots represent 
data above the significance level. (d) Volcano plot showing difference in methylation treated NBM vs 
untreated NBM. No blue dots, that is, no data reached the significance level. 
 
 
5.3 PAPER III 
MUTATIONS IN HISTONE MODULATORS AND HOXA5 METHYLATION LEVELS PREDICT 
SURVIVAL IN AZACITIDINE TREATED MDS PATIENTS 
 
Only around 50% of patients respond to treatment with Azacitidine, and at least one 
third of patients show no response at all or even disease progression. Since it usually 
takes 6 months to define a non-responder, it is clinically highly relevant to identify 
predictive factors for response. This study aimed to identify clinically relevant 
predictors for the efficacy of Azacitidine treatment at three different levels: basic 
clinical parameters, mutational status, and methylation profiles.  
We first evaluated standard clinical parameters and identified disease duration as a 
factor associated with poor response to treatment and shorter survival estimated from 
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start of Azacitidine therapy.  Cytogenetic risk profile was associated with survival but 
not with response, see Figure 11. High ANC counts did not affect response rates but 
were associated with shorter survival. There was a trend towards lower response rates 
and shorter survival for transfusion-dependent patients, in analogy to our findings in 
paper I. 
 The second part of the study evaluated the impact of mutational status on response and 
survival. Recently, Traina et al reported a study of around 40 higher-risk patients and 
showed better response rates for patients carrying a TET2 and/or DNMT3A mutation in 
a cohort of MDS-patients.
246
 In our material of 90 patients, there was only a trend 
towards higher response rates in patients with epigenetic mutations including histone 
modulator mutations and DNA methylation mutations. Unexpectedly, while mutations 
in genes encoding DNA methylation enzymes had no impact on survival, patients 
presenting with mutations in the group of genes encoding histone modulators (ASXL1, 
EZH2, MLL) showed significantly better survival (p=0.01), a finding that retained 
significance in the multivariate analysis. ASXL1-mutation alone showed a trend towards 
prolonged survival in our material, contrasting the results from the study by Traina 
where ASXL1 was reported as a negative marker, possibly due to the lower proportion 
of higher-risk MDS patients in the Traina study. In addition to ASXL1 and EZH2, other 
well-known adverse genetic events, such as RUNX1 and TP53 mutations, and the 
number of mutations were neutralized as adverse prognostic factors by Azacitidine 
treatment.  
Thirdly, we examined the role of global DNA methylation by analyzing genome-wide 
DNA methylation in MNCs using Illumina methylation array 450k. By studying 
differentially methylated regions (DMRs) we could identify specific differences in the 
pre-treatment profiles between responding and non-responding patients. The DMRs 
were strongly enriched for genes involved in development and differentiation 
pathways. Six HOX-genes were differentially methylated of which HOXA5 was the 
most significant. By comparing our data with methylation data from different 
maturation stages in normal hematopoiesis, we showed that non-responders had a 
HOXA5 methylation pattern closer to that of progenitor cells while responders 
resembled more differentiated cells, see Figure 12. Furthermore we could demonstrate 
that patients with higher methylation level of HOXA5 had a longer survival compared 
to lower-methylation (p=0.03). 
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Figure 11: Survival after start of Azacitidine stratified for pre-treatment parameters and response 
 
 
 
 
Figure 12: DNA methylation levels at the HOXA5 locus. Squares represent gene location with light green=TSS-
1500; Dark green=TSS-200; Red=Gene body; Magenta=1st Exon; Dark blue=5’UTR; Cyan=3’UTR and 
diamonds represent sample values. A=Median methylation level of responders illustrated with orange 
diamonds (MNCs) and non-responders with blue diamonds (MNCs). B=Added CD34+ cells with red 
diamonds.  C=All patients.  D=Normal bone marrow with PMN illustrated with brown diamonds and CMP 
with green diamonds. 
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5.4 PAPER IV 
IN VITRO EXPOSURE TO AZACITIDINE INDUCES DEMETHYLATION AND INCREASED 
GENE EXPRESSION IN PRIMARY MDS PROGENITOR CELLS. 
 
As demonstrated in paper II, Azacitidine has a clear demethylating effect on primary 
MDS cells during cell culture. The effect on gene expression is however still unclear. In 
this paper we investigated the impact of in vitro exposure to Azacitidine on both DNA 
methylation and gene expression in primary MDS cells.  
Bone marrow samples from 11 consecutive patients with a clinical indication for 
Azacitidine treatment, i.e. MDS with IPSS int-2 or high, CMML with >10% blasts or 
AML with multilinear dysplasia and <30% blasts, were collected. After separation of 
CD34+ cells, samples proceeded to cell culture freshly without any freezing / thawing 
step in between.  Since there is no consensus regarding culture conditions for studying 
the Azacitidine-effects, we cultured cells with or without Azacitidine, and harvested 
cells after 0, 24 and 48 hours of culture in order to study the impact of different 
exposure time and to study if the culture procedure itself alters the epigenome and 
transcriptome.  The culture conditions were identical to those described in paper II 
including the same dose, 1µM of Azacitidine.   
Sample material allowed assessment of differences in methylation status between 
samples cultured with or without Azacitidine for 24h (n=9), samples cultured without 
treatment  for 0h or 24h (n=4), samples cultured without treatment for 24h or 48h (n=2) 
and samples cultured with Azacitidine for 24h or 48h (n=4).  DNA methylation was 
studied using the Illumina 450k platform. We observed no differences in global 
methylation pattern when comparing samples cultured without Azacitidine for 0h and 
24h or for samples cultured for 24h and 48h without Azacitidine, see Figure 13. When 
comparing samples cultured with or without Azacitidine for 24h, we could, as 
expected, reproduce the same methylation pattern as was seen in the cohort used for 
paper II.  
By comparing sampled cultured for 24h with or without Azacitidine, we identified a 
large number (n=65 769) of differentially methylated probes (DMPs). The vast 
majority of these were less methylated in the Azacitidine samples. Furthermore, we 
identified between 94 and 1822 DMRs, depending on DMR calling algorithm used. 
Pathway analysis of the genes associated to the DMRs showed a strong enrichment for 
biological processes involved in cellular differentiation and development.   
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Due to low RNA concentration, samples from 6 of the patients underwent a 
concentrating procedure by SpeedVac ™. The concentrated samples clustered together 
in a principal component analysis and were separated from the non-concentrated 
samples, probably reflecting RNA degradation during the concentration procedure, and 
these samples were excluded from further analyses. Hence, gene expression could be 
evaluated in paired samples from 4 patients, comparing 24h Azacitidine vs. 24h 
control, 2 patients comparing 24 h vs. 48 control and 2 patients comparing 24 h vs. 48 h 
Azacitidine.  
Comparing treated and untreated cells cultured for 24 h, we observed an increase in 
total polyadenylated RNA in the Azacitidine samples in all four patients. A total 
number of 3855 transcripts, corresponding to 2136 genes, were differentially expressed 
between treated and non-treated cells (Figure 14A). The vast majority of these 
(n=3850) were upregulated. Pathway analysis of the upregulated genes showed 
enrichment of a variety of pathways including translation, cellular component 
disassembly and RNA processing. Of the upregulated genes, 104 were transcription 
factors and 24 were epigenetic regulators. Comparing samples with and without 
Azacitidine for 24 and 48 hours did not show any significant skewedness in gene 
expression, see Figure 14B and 14C.   
Interestingly, DMRs and genes with increased expression showed very limited overlap. 
Moreover, the percentage of the total number of transcripts upregulated in the selected 
DMR-associated genes was 73%, as compared to 77% for the whole transcriptome. 
Hence, no direct relation between genes associated with DMRs and increased gene 
expression was observed. By selecting the promotor-related probes we could see a 
general slight decrease (9.6%) in methylation level (using beta level as output from the 
Illumina array) but there was no correlation between mean methylation level and 
relative change in gene expression.  It is unclear if the promotor demethylation is 
causing increased gene expression. 
To further explore the reasons for the observed discrepancy, we next designed primers 
for the promoter regions of three genes (Glrx3, AKAP12 and NUP210) associated with 
demethylated regions in the Azacitidine samples without increase in gene expression. 
ChIP was performed on samples cultured for 24 h with or without Azacitidine, from the 
same individual patients that we obtained RNA seq results from. We used the 
repressive chromatin mark H3K9me3, whereafter qPCR for the three genes was 
performed. Two genes were neither transcribed at all in the control samples nor in the 
treated samples, and one was transcribed in the control sample with preserved 
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transcription in the treated sample. Glrx3 increased repressive chromatin mark 
H3K9me3 by on average 5 fold, AKAP12 by 4.2 fold, and NUP210 by 2.6 fold on 
average, in the three different patients assessed. Azacitidine is thus affecting the 
chromatin inducing an increase in repressive mark, providing a potential explanation 
why these genes do not gain increased expression despite demethylation. 
 
 
Figure 13: Volcano plot illustrating differences in methylation for the comparisons: A). Azacitidine vs. control 
after 24 h of culture B) Azacitidine cultured for 48 h vs. 24 h  C) Azacitidine cultured for 48 h vs. control 
cultured for 48 h D) Control cultured for 24 h vs no culture (0h)  
 
Figure 14: Illustration of differences in gene expression, comparing samples A) cultured for 24 h with or 
without Azacitidine; B) samples without Azacitidine, cultured for 24 h vs 48 h; and C) samples with 
Azacitidine, cultured for 24 h vs 48 h . Red dots indicate statistically significant values (FDR<0.05) and blue 
dots indicate top 100 up / down regulated. 
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6 FUTURE PERSPECTIVES 
 
Azacitidine has changed the way we treat patients with higher-risk MDS and has 
resulted in prolonged survival and improved quality of life for a proportion of these 
patients. However, despite the progress made with the advent of Azacitidine, the 
prognosis for patients with higher risk MDS is still very poor why improved treatment 
for this group of patients is highly warranted. The clinical experience of Azacitidine is 
rapidly increasing but many clinical questions remain to be scrutinized; can predictive 
markers discriminating responding from non-responding patients be identified allowing 
physicians to avoid Azacitidine treatment in patients without clinical benefit; what is 
the optimal dosing regimen and administration route; what is the role of Azaciditine 
before and after stem cell transplantation and what drug combinations can improve 
outcome. 
 
Azacitidine has also opened a new field of epigenetic treatment which has just recently 
started and which will be in focus of cancer research for a long time. This field 
demands a broader collaboration between basic epigenetic researchers and clinical 
andtranslational researchers but also calls for knowledge in various other fields like 
immunology, genetics, and pharmacology. 
 
Still, more than 50 years since Azacitidine was first used in hematological 
malignancies, the mechanism of it´s action is largely unknown. Although several 
mechanisms, and most importantly the demethylating effect, have been described, the 
essential processes involved in the Azacitidine-effect are yet to be explored. A deeper 
understanding of these mechanisms is crucial in order to develop better drugs and find 
successful combinations with other drugs. The demethylating effect is maybe still the 
best clue to understand the pharmacodynamics of Azacitidine and further studies on 
this field are warranted using methods with higher sensitivity and using improved 
bioinformatic tools for translating methylation data into biological models. However, 
several other areas of research should be in focus and most importantly the effects on 
chromatin structure, direct effects on RNA, effects on the micro-environment and the 
immune system.  
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7 SAMMANFATTNING PÅ ENKEL SVENSKA 
 
Myelodysplastiskt syndrom (MDS) är en grupp elakartade blodsjukdomar som har sitt 
ursprung i de blodbildande stamcellerna i benmärgen. MDS drabbar ca 400 svenskar 
varje år. Förekomsten ökar med stigande ålder och medianåldern vid diagnos är drygt 
70 år. Sjukdomen är ovanlig före 50 års ålder. Symtomen vid MDS är relaterade till 
brist på en eller flera typer av blodceller och det ger symtom i form av trötthet, 
infektionsbenägenhet och blödningar. Hos ungefär en tredje del av patienterna går 
sjukdomen över i en akut leukemi. Sjukdomen kan uppträda med ett mer långsamt 
förlopp (lågrisk MDS) eller som en mer aggressiv sjukdom som påminner om en 
leukemi (högrisk MDS). 
Mekanismerna som gör att sjukdomen uppträder är ofullständigt kända. Vi vet att 
skador på arvsmassan (DNA) bidrar till sjukdomens uppkomst.  Skadorna kan uppträda 
dels genom stora strukturella förändringar på kromosomerna t.ex. kan delar av 
kromosom 5 eller 7 falla bort, eller som mutationer på enskilda gener d.v.s. den 
genetiska koden ändras på en specifik plats i arvsmassan. Man har idag identifierar ett 
40-tal gener där man har sett mutationer som kan kopplas till MDS-sjukdomen. Vilka 
gener som har skadats vid MDS har betydelse för prognosen och utvecklingen av 
sjukdomen men detaljerad kunskap om detta och hur mutationerna bidrar till 
uppkomsten av sjukdomen är fortsatt ofullständig. 
Utöver genetiska skador bidrar även epigenetiska skador till uppkomsten av 
sjukdomen.  Epigenetik innebär att cellen har egenskaper som nedärvs till dotterceller 
utan att själva arvsmassan påverkas. Denna information, som ger cellen en specifik 
signatur och identitet, regleras genom bl.a. DNA metylering och histonmodifikationer 
och har stor betydelse vid utmognaden av blodbildande celler från stamceller till 
färdiga blodceller. Vid MDS har man visat att det föreligger en ökad DNA metylering 
jämfört med friska celler vilket sannolikt medverkar till att utmognaden vid MDS är 
störd. 
Azacitidine är ett cellgift som har visat sig förlänga överlevnaden vid MDS vilket man 
kunnat konstatera genom att i stora studier slumpmässgt lotta patienten till att få 
antingen Azacitidine eller konventionell behandling t.ex. blodtransfusioner eller 
klassiska cellgifter. Effekten av Azacitdine är i stora delar oklar men man tror att 
Azacitidine har en epigenetisk effekt då man sett att DNA metyleringen minskar till 
följd av att Azacitidine hämmar de enzym som leder till DNA metylering.  
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I vår första studie ville vi undersöka om Azacitidine utöver att ha effekt på högrisk 
MDS, även kunde ha effekt vid lågrisk MDS. Vi valde ut patienter som hade en uttalad 
blodbrist till följd av sjukdomen och krävde regelbundna blodtransfusioner. Dessa 
patienter hade tidigare behandlats med Epo, ett hormon som stimulerar blodbildningen, 
utan att ha effekt. Dessa patienter behandlades med Azacitidine i 6 månader. De 
patienter som fortsatt behövde blodtransfusioner fick ytterligare 3 månaders behandling 
med tillägg av Epo. Vi behandlade 30 patienter varav 6 efter behandling inte längre 
behövde blodtransfusioner.  Det uppstod 38 fall av allvarliga biverkningar, varav den 
vanligaste orsaken var infektion vilket krävde inläggning på sjukhus. 
Sammanfattningsvis var studien en besvikelse där endast en mindre andel av 
patienterna hade nytta av behandlingen medan antalet allvarliga biverkningar var 
relativt stor och vår konklusion är att behandlingen inte ska ges rutinmässigt till dessa 
patienter men kan övervägas i särskilda tillfällen. 
I vårt andra och fjärde arbete har vi studerat hur celler från patienter med MDS reagerar 
på att i laboratorium exponeras för Azacitidine och jämförde med celler från friska 
försökspersoner. Vi kunde till att börja med konstatera att Azacitidine, trots att det är ett 
cellgift, i låga doser motsvarande de man ger till patienter, inte har någon avdödande 
effekt på vare sig MDS-celler eller friska celler. Tvärtom kunde man vid s.k. 
koloniexperiment där celler får växa i ett odlingsmedium under två veckors tid, att låga 
doser Azacitidine snarar stimulerade tillväxt av MDS celler. Det faktum att Azacitidine 
inte har någon avdödande effekt på MDS-celler i dessa doser gör att vi inte tror att 
behandlingseffekten av Azacitidine orsakas av en cellgiftseffekt utan att den har andra 
orsaker t.ex. epigenetisk påverkan. Vi undersökte därefter effekt på DNA metylering 
genom en så kallad metyleringsarray som undersöker metyleringen på 480 000 platser i 
avsmassan. Vi jämförde MDS celler med friska celler och kunde konstatera att MDS 
cellerna hade en högre metyleringsnivå på många av generna. Vidare kunde vi 
konstatera att de MDS-celler som odlats tillsammans med Azacitidine hade en lägre 
metyleringsnivå på en stor del av de undersökta platserna jämfört med de MDS-celler 
som odlats utan Azacitidine och således minskar Azacitidine metyleringen. Vi 
undersökte också en annan epigenetisk mekanism: histon acetylering och kunde något 
förvånande konstatera att histonacetyleringen minskar vilket innebär ett minskat uttryck 
av gener tvärtemot den förväntade effekten av minskad metylering. Möjligen kan 
minskad histonacetylering leda till att MDS-celler är motståndskraftiga mot Azacitidine 
vilket skulle tala för att dessa patienter också behöver läkemedel inriktade mot att öka 
   49 
histonacetyleringsnivån. I vårt fjärde arbete upprepade vi de odlingsförsök som låg till 
grund för arbete två. Vi kunde återigen se att Azacitidine minskade metyleringen. Vi 
kunde också se att uttrycket av gener ökade vilket är förväntat som ett resultat av 
minskad metylering. Förvånande nog verkar det inte vara specifikt de gener som får 
minskad metylering som också får ökat genuttryck vilket man skulle förvänta sig. 
Möjligen föreligger det indirekta effekter t.ex. direkt påverkan på RNA eller påverkan 
på s.k. transkriptionsfaktorer som i sin tur påverkar genuttrycket. En annan effekt vi såg 
var att Azacitidine verkar få kromatinet att sluta sig vilket vi kunde mäta genom att 
studera en ytmarkör på kromatinet som kallas H3K9me3. Denna ytmarkör avspeglar ett 
slutet kromatin där gener inte kan uttryckas och Azacitidinbehandlade celler hade högre 
signal av H3K9me3 än obehandlade celler. Vi kan konstatera att de epigenetiska 
effekterna av Azacitidin är komplexa och ytterligare studier som studerar olika 
epigenetiska aspekter behöver genomföras. 
 
I vårt tredje arbete letade vi efter faktorer som kan hjälpa oss att förutse vilka patienter 
som kommer att svara på behandling med Azacitidine. Ungefär hälften av alla patienter 
svarar på behandlingen och inga tillförlitliga studier har kunnat förklara vilka patienter 
som har nytta av behandlingen. Många patienter får således behandlingen i onödan. Vi 
sammanställde all tillgänglig information från journaler på alla de 134 patienter som 
fått Azacitidine vid MDS på Karolinska sjukhuset. Vi kunde konstatera att varken 
blodprover, benmärgsprov eller kromosomskador d.v.s. de undersökningar som görs på 
alla patienter med sjukdomen, ger information om vilka patienter som svarar på 
behandlingen. Vidare genomförde vi en DNA sekvensering på de gener som kunnat 
kopplas till sjukdomen på 90 av patienterna och undersökte om mutationer i dessa 
gener kan förutse vilka som svarar på behandlingen. Vi fann då att de patienter som 
hade mutationer i någon av de tre gener som påverkar histoner levde längre än de 
patienter som inte har någon sådan mutation. Detta kan vara ett viktigt verktyg för 
läkare som behandlar patienter med MDS då förekomsten av dessa mutationer skulle 
ökar chansen för att Azacitidine kommer att vara verkningsfullt. Vi undersökte också 
metylering med en metyleringsarray beskriven ovan på 42 patienter och sökte efter 
skillnader i metyleringsmönster mellan de patienter som svarade och de som inte gjorde 
det. Vi fann att metyleringsnivåerna skiljde sig på 200 gener och att en stor andel av 
dessa gener var sådana som styrde utmognadsprocessen av blodbildande celler. Vi 
jämförde vidare våra resultat med metyleringsnivå på sorterade MDS-stamceller och 
benmärg från friska försökspersoner och kunde konstatera att de patienter som inte 
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svarar har ett metyleringsmönster som mer liknar stamceller medan de patienter som 
svara har ett metyleringsmönster som mer liknar utmognade celler. Slutligen kunde vi 
konstatera att metyleringsnivån på den gen som skilde sig tydligast mellan de patienter 
som svarade och de som inte svarade, HOXA5, har betydelse för överlevnaden, där 
patienter med högre metyleringsnivå har en bättre överlevnad. 
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